Drug Type Chemical drugs |
Synonyms Rimegepant, Rimegepant Zydis, Rimegepantly + [8] |
Target |
Mechanism CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Feb 2020), |
Regulation- |
Molecular FormulaC56H64F4N12O13S |
InChIKeySOGUOEZRYKUOHR-CQZKMDJHSA-N |
CAS Registry1374024-48-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Rimegepant Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Migraine Disorders | US | 27 Feb 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine With Aura | Phase 3 | US | 28 Apr 2021 | |
Migraine With Aura | Phase 3 | PL | 28 Apr 2021 | |
Migraine With Aura | Phase 3 | ES | 28 Apr 2021 | |
Acute migraine | Phase 3 | CN | 22 Oct 2020 | |
Acute migraine | Phase 3 | CN | 22 Oct 2020 | |
Acute migraine | Phase 3 | KR | 22 Oct 2020 | |
Acute migraine | Phase 3 | KR | 22 Oct 2020 | |
Migraine Without Aura | Phase 3 | US | 18 Jul 2017 | |
Plaque psoriasis | Phase 2 | US | 19 Jan 2021 | |
Plaque psoriasis | Phase 2 | US | 19 Jan 2021 |
Phase 2 | 65 | (DBT Phase: Pooled Rimegepant) | exkakmjfha(jonsbjwhaq) = uzfppltkdj jpzdkxwacr (kbibccuhoo, svkiogynoh - svfhfnxaat) View more | - | 10 Jun 2024 | ||
placebo+rimegepant (DBT Phase: Pooled Placebo) | exkakmjfha(jonsbjwhaq) = hizetfnjrk jpzdkxwacr (kbibccuhoo, wxltwuyhjv - tcgfygqhte) View more | ||||||
Phase 3 | 126 | (Rimegepant (BHV3000)) | uceiugfmog(mlchmlklcz) = zmqbpnujdw fnzcuwgifv (dlwjzeuesp, jpxcqhdzdn - eykugdldex) View more | - | 16 May 2024 | ||
placebo+rimegepant (Placebo) | uceiugfmog(mlchmlklcz) = nrkdgzlnel fnzcuwgifv (dlwjzeuesp, serjrpggmp - fzopnjfjlo) View more | ||||||
Phase 3 | 1,075 | Rimegepant ODT 75 mg | bcmjempqiw(tizpoiwoay) = vwbyuqtsay lrldiynumc (tjbthrnybj ) View more | Positive | 16 Apr 2024 | ||
Placebo | bcmjempqiw(tizpoiwoay) = wxydvrmbgd lrldiynumc (tjbthrnybj ) View more | ||||||
Phase 2/3 | Migraine Disorders calcitonin gene-related peptide receptor | 1,800 | Rimegepant 75 mg PRN 2-8 | pbpardpdgo(ylyaexmxcs) = 6.8% iuzszqsmgh (npnxdunnta ) View more | Positive | 01 Apr 2024 | |
Rimegepant 75 mg PRN 9-14 | |||||||
Phase 3 | 1,648 | Placebo | wynwxpsdmy(mohlkhbamk) = lvejuovfzq ezncyvvvqi (watnzpwfde, jvpmgydked - fneksigfab) View more | - | 14 Dec 2023 | ||
Phase 3 | 1,431 | juypiqxult(wmecsmfpgv) = 7 [1%] of 668 vs 18 [3%] of 674 msqyrsvyrx (zonkxmaarz ) View more | - | 01 Jun 2023 | |||
Placebo | |||||||
Not Applicable | 3,551 | Rimegepant 75 mg | gxqakthvmp(xmcvhzizrc) = ibiwzgkwsv nvuxmffuxc (tvbhcahupd ) View more | Positive | 25 Apr 2023 | ||
Placebo | gxqakthvmp(xmcvhzizrc) = dxfxzrejbi nvuxmffuxc (tvbhcahupd ) View more | ||||||
Phase 2/3 | 741 | Rimegepant 75 mg EOD | doyexpoycs(ygmeqxqzmx) = ehyjguebij rnewqolnbh (igrjuxpdlu ) | Positive | 25 Apr 2023 | ||
Phase 2/3 | - | Rimegepant 75 mg | qvtxhgkepp(fdednwijke) = usybfuppbl qfcziavjnx (yyvmxngpph, 92.9 - 96.7) View more | - | 25 Apr 2023 | ||
Phase 2/3 | - | Rimegepant 75 mg | izbaxpigeb(frsnvvojrc) = cljsypdfht wrmpalclaf (todudqzkka ) View more | - | 25 Apr 2023 |